Selected research
Industry Research
Proprotein Convertase Subtilisin & Kexin Type 9 Industry Research Report 2026
Market perspective
The global Proprotein Convertase Subtilisin & Kexin Type 9 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Proprotein Convertase Subtilisin & Kexin Type 9 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Proprotein Convertase Subtilisin & Kexin Type 9 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Proprotein Convertase Subtilisin & Kexin Type 9 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Proprotein Convertase Subtilisin & Kexin Type 9 include Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Novartis AG, Eli Lilly and Co, Pfizer Inc, The Medicines Company, Serometrix LLC, Regeneron Pharmaceuticals Inc, Kowa Co Ltd and Ensemble Therapeutics Corp, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Proprotein Convertase Subtilisin & Kexin Type 9 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Proprotein Convertase Subtilisin & Kexin Type 9.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Proprotein Convertase Subtilisin & Kexin Type 9 Market by Company
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Novartis AG
Eli Lilly and Co
Pfizer Inc
The Medicines Company
Serometrix LLC
Regeneron Pharmaceuticals Inc
Kowa Co Ltd
Ensemble Therapeutics Corp
Dicerna Pharmaceuticals Inc
Catabasis Pharmaceuticals Inc
BioLingus AG
Bioleaders Corp
Betagenon AB
AFFiRiS AG
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Type
SX-PCK9
O-304
K-312
DCRPCSK-9
BLSM-201
Others
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Application
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proprotein Convertase Subtilisin & Kexin Type 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Proprotein Convertase Subtilisin & Kexin Type 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proprotein Convertase Subtilisin & Kexin Type 9.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Proprotein Convertase Subtilisin & Kexin Type 9 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- SX-PCK9
- O-304
- K-312
- DCRPCSK-9
- BLSM-201
- Others
Applications
- Cardiovascular Disease
- Homozugous Familial Hyperchalesterolemia
- Liver Disease
- Metabolic Syndrome
- Others
Companies covered
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Novartis AG
- Eli Lilly and Co
- Pfizer Inc
- The Medicines Company
- Serometrix LLC
- Regeneron Pharmaceuticals Inc
- Kowa Co Ltd
- Ensemble Therapeutics Corp
- Dicerna Pharmaceuticals Inc
- Catabasis Pharmaceuticals Inc
- BioLingus AG
- Bioleaders Corp
- Betagenon AB
- AFFiRiS AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Proprotein Convertase Subtilisin & Kexin Type 9 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 SX-PCK9
- 2.2.3 O-304
- 2.2.4 K-312
- 2.2.5 DCRPCSK-9
- 2.2.6 BLSM-201
- 2.2.7 Others
- 2.3 Proprotein Convertase Subtilisin & Kexin Type 9 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cardiovascular Disease
- 2.3.3 Homozugous Familial Hyperchalesterolemia
- 2.3.4 Liver Disease
- 2.3.5 Metabolic Syndrome
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Proprotein Convertase Subtilisin & Kexin Type 9 Breakdown Data by Type
- 3.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Historic Market Size by Type (2021-2026)
- 3.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Type (2027-2032)
4 Proprotein Convertase Subtilisin & Kexin Type 9 Breakdown Data by Application
- 4.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Historic Market Size by Application (2021-2026)
- 4.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Perspective (2021-2032)
- 5.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Growth Trends by Region
- 5.2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Proprotein Convertase Subtilisin & Kexin Type 9 Historic Market Size by Region (2021-2026)
- 5.2.3 Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Region (2027-2032)
- 5.3 Proprotein Convertase Subtilisin & Kexin Type 9 Market Dynamics
- 5.3.1 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Trends
- 5.3.2 Proprotein Convertase Subtilisin & Kexin Type 9 Market Drivers
- 5.3.3 Proprotein Convertase Subtilisin & Kexin Type 9 Market Challenges
- 5.3.4 Proprotein Convertase Subtilisin & Kexin Type 9 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Players by Revenue
- 6.1.1 Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Players by Revenue (2021-2026)
- 6.1.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Players (2021-2026)
- 6.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Proprotein Convertase Subtilisin & Kexin Type 9 Head Office and Area Served
- 6.4 Global Proprotein Convertase Subtilisin & Kexin Type 9 Players, Product Type & Application
- 6.5 Global Proprotein Convertase Subtilisin & Kexin Type 9 Manufacturers Established Date
- 6.6 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2021-2032)
- 7.2 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2021-2026)
- 7.4 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2021-2032)
- 8.2 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2021-2026)
- 8.4 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2021-2032)
- 9.2 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2021-2032)
- 10.2 South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2021-2026)
- 10.4 South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2021-2032)
- 11.2 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- 12.1.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Information
- 12.1.2 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview
- 12.1.3 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.1.4 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.1.5 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.2.4 Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Eli Lilly and Co
- 12.3.1 Eli Lilly and Co Company Information
- 12.3.2 Eli Lilly and Co Business Overview
- 12.3.3 Eli Lilly and Co Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.3.4 Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.3.5 Eli Lilly and Co Recent Developments
- 12.4 Pfizer Inc
- 12.4.1 Pfizer Inc Company Information
- 12.4.2 Pfizer Inc Business Overview
- 12.4.3 Pfizer Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.4.4 Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.4.5 Pfizer Inc Recent Developments
- 12.5 The Medicines Company
- 12.5.1 The Medicines Company Company Information
- 12.5.2 The Medicines Company Business Overview
- 12.5.3 The Medicines Company Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.5.4 The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.5.5 The Medicines Company Recent Developments
- 12.6 Serometrix LLC
- 12.6.1 Serometrix LLC Company Information
- 12.6.2 Serometrix LLC Business Overview
- 12.6.3 Serometrix LLC Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.6.4 Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.6.5 Serometrix LLC Recent Developments
- 12.7 Regeneron Pharmaceuticals Inc
- 12.7.1 Regeneron Pharmaceuticals Inc Company Information
- 12.7.2 Regeneron Pharmaceuticals Inc Business Overview
- 12.7.3 Regeneron Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.7.4 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.7.5 Regeneron Pharmaceuticals Inc Recent Developments
- 12.8 Kowa Co Ltd
- 12.8.1 Kowa Co Ltd Company Information
- 12.8.2 Kowa Co Ltd Business Overview
- 12.8.3 Kowa Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.8.4 Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.8.5 Kowa Co Ltd Recent Developments
- 12.9 Ensemble Therapeutics Corp
- 12.9.1 Ensemble Therapeutics Corp Company Information
- 12.9.2 Ensemble Therapeutics Corp Business Overview
- 12.9.3 Ensemble Therapeutics Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.9.4 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.9.5 Ensemble Therapeutics Corp Recent Developments
- 12.10 Dicerna Pharmaceuticals Inc
- 12.10.1 Dicerna Pharmaceuticals Inc Company Information
- 12.10.2 Dicerna Pharmaceuticals Inc Business Overview
- 12.10.3 Dicerna Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.10.4 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.10.5 Dicerna Pharmaceuticals Inc Recent Developments
- 12.11 Catabasis Pharmaceuticals Inc
- 12.11.1 Catabasis Pharmaceuticals Inc Company Information
- 12.11.2 Catabasis Pharmaceuticals Inc Business Overview
- 12.11.3 Catabasis Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.11.4 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.11.5 Catabasis Pharmaceuticals Inc Recent Developments
- 12.12 BioLingus AG
- 12.12.1 BioLingus AG Company Information
- 12.12.2 BioLingus AG Business Overview
- 12.12.3 BioLingus AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.12.4 BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.12.5 BioLingus AG Recent Developments
- 12.13 Bioleaders Corp
- 12.13.1 Bioleaders Corp Company Information
- 12.13.2 Bioleaders Corp Business Overview
- 12.13.3 Bioleaders Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.13.4 Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.13.5 Bioleaders Corp Recent Developments
- 12.14 Betagenon AB
- 12.14.1 Betagenon AB Company Information
- 12.14.2 Betagenon AB Business Overview
- 12.14.3 Betagenon AB Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.14.4 Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.14.5 Betagenon AB Recent Developments
- 12.15 AFFiRiS AG
- 12.15.1 AFFiRiS AG Company Information
- 12.15.2 AFFiRiS AG Business Overview
- 12.15.3 AFFiRiS AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2021-2026)
- 12.15.4 AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.15.5 AFFiRiS AG Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst